Priority
Focus
– Urothelial
Cancer
Editorial
by
Brant
Inman
and
Kae
Jack
Tay
on
pp.
64–65
of
this
issue
Impact
of
Combined Use
of
Blood-based
Inflammatory Markers
on
Patients with Upper
Tract Urothelial
Carcinoma
Following
Radical Nephroureterectomy:
Proposal
of
a
Cumulative Marker
Score
as
a Novel
Predictive
Tool
for
Prognosis
Nobuyuki
Tanaka
a ,Eiji Kikuchi
a , * ,Kent Kanao
a ,Kazuhiro Matsumoto
a , b ,Suguru
Shirotake
a ,Yasumasa Miyazaki
a ,Hiroaki
Kobayashi
a , c ,Gou Kaneko
a , d ,Masayuki Hagiwara
a , e ,Hiroki
Ide
a , f ,Jun Obata
a ,Katsura Hoshino
a ,Nozomi Hayakawa
a , b ,Takeo Kosaka
a , g ,Satoshi Hara
d ,Ken Nakagawa
e ,Masahiro
Jinzaki
h ,Mototsugu Oya
aa
Department of Urology, Keio University School of Medicine, Tokyo,
Japan;
b
Department of Urology, Saiseikai Central Hospital, Tokyo,
Japan;
c
Department of
Urology,
Kyosai
Tachikawa
Hospital,
Tokyo,
Japan;
d
Department
of
Urology,
Kawasaki
City
Hospital,
Tokyo,
Japan;
e
Department
of
Urology,
Ichikawa
General Hospital,
Tokyo Dental
College,
Ichikawa,
Japan;
f
Department
of Urology,
Inagi
City Hospital,
Tokyo,
Japan;
g
Department
of Urology,
Irumagawa
Hospital,
Saitama,
Japan;
h
Department
of Diagnostic
Radiology,
Keio University
School
of Medicine,
Tokyo,
Japan
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 5 4 – 6 3available
at
www.sciencedirect.comjournal
homepage:
www.europeanurology.comArticle
info
Article
history:
Accepted
February
4,
2015
Associate
Editor:
Gianluca Giannarini
Keywords:
Urothelial
carcinoma
Upper
urinary
tract
C-reactive
protein
Neutrophil-to-lymphocyte
ratio
Fibrinogen
Outcome
Prognosis
Marker
score
Abstract
Background:
Previous studies showed
the prognostic
impact of preoperative
levels of neutrophil-to-
lymphocyte
ratio
(NLR), plasma
fibrinogen,
and
serum C-reactive protein
(CRP)
in
surgically
treated
upper
tract urothelial carcinoma; however,
few papers have discussed
the proper use of these
indices.
Objective:
To
investigatewhether combinations of these threemarkers, as a cumulativemarker score
(CMS),
improve
the
accuracy
of prognostic models
following
radical nephroureterectomy
(RNU).
Design,
setting, and participants:
A
total of 394 patients
from multiple
institutions were
included.
Median
follow-up was
30 mo.
Intervention:
All
patients
underwent
RNU without
neoadjuvant
chemotherapy.
Outcome measurements
and
statistical
analysis:
Associated
outcomes were
assessed
using mul-
tivariate
analysis.
The
CMS was
defined
as
the
number
of
elevated
levels
of
preoperative
NLR,
plasma
fibrinogen,
and
serum
CRP.
Results and
limitations:
Multivariate analyses
revealed
that an
increasing CMS was
independently
associated with high
rates of disease
recurrence,
cancer-specific mortality, and all-cause mortality
following RNU. Addition of
the CMS
to a model
that
included
standard clinicopathologic predictors
significantly
improved predictive
accuracy by 2.7%
for disease
recurrence, 3.9%
for
cancer-specific
mortality, and 4.0%
for all-cause mortality, which were
the highest among other prognostic models
using
each marker
alone
or
combinations
of
two.
The
study
is
limited
by
its
retrospective nature.
Conclusions:
Although
the
use
of
each
inflammatory
marker
alone
may
be
as
predictive
as
clinicopathologic
indices
for
prognosis,
combinations
like
CMS
can
provide more
accurate
prog-
nostic models
following
RNU.
Patient
summary:
Elevation
of
blood-based
inflammatory markers may
be
useful
for
predicting
prognosis
because
of
their
low
cost
and
accessibility.
Among
blood-based
indices, we
examined
the efficacy of preoperative neutrophil-to-lymphocyte ratio, plasma fibrinogen, and serumC-reactive
protein
levels.
Although
use
of
each
marker
alone
provides
additional
prognostic
information,
the combination of all
three markers would be more predictive
than any
single marker or combina-
tions
of
two.
#
2015
European Association
of Urology.
Published
by
Elsevier B.V.
This
is
an
open
access
article
under
the
CC
BY-NC-ND
license
( http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author. Department of Urology, Keio University School of Medicine, 35 Shinanomachi,
Shinjuku-ku, Tokyo 160-8582,
Japan. Tel.
+81
3
5363
3825;
Fax:
+81
3
3225 1985.
address:
eiji-k@kb3.so-net.ne.jp(E. Kikuchi).
http://dx.doi.org/10.1016/j.euf.2015.02.0012405-4569/
#
2015 European Association of Urology. Published by Elsevier B.V. This
is an open
access
article under
the CC BY-NC-ND
license
( http:// creativecommons.org/licenses/by-nc-nd/4.0/ ).




